Curocell Seeks Approval to Amend Phase 3 Lymphoma Trial Plan

Bitget2026/10/30 07:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Curocell applied to South Korea's MFDS on Oct. 30, 2026, for approval to amend its CRC01 Phase 3 trial plan.
The trial will compare CRC01 with standard treatment in approximately 136 adults with relapsed or refractory large B-cell lymphoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curocell Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030900803), on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Curocell Seeks Approval to Amend Phase 3 Lymphoma Trial Plan

You may also like

Crypto prices